Related Industry Reports:
Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.
PloS one 2012 Jan 1; In press
Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, Ballard C, Boustani M, Katona C, Livingston G
Department of Psychiatry, University of East Anglia, Norwich, United Kingdom.
Agitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary hypothesis, memantine is superior to placebo for clinically significant agitation, in patients with moderate-to-severe AD.